急性片頭痛治療の世界市場レポート 2025年

急性片頭痛治療市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR11.2％で44億4,000万米ドルに成長します。予測期間の成長は、片頭痛の有病率の増加、片頭痛研究への投資の増加、非侵襲的治療オプションへの需要の高まり、即効性のある緩和オプションへの需要の高まり、患者中心の医薬品開発の重視の高まりに起因しています。予測期間における主な動向としては、技術の進歩、神経調節装置の採用、個別化医療、遠隔医療、診断ツールなどが挙げられます。

仕事のプレッシャーの増大は、急性片頭痛治療市場の成長を牽引すると予測されます。仕事のプレッシャーとは、職務上の要求や課題によって従業員が経験する精神的、感情的、身体的負担を指します。ワークプレッシャー増加の要因としては、厳しい納期、リソースやサポートの不足、ワークライフバランスの悪さ、職務上の役割の不明確さ、人間関係の衝突、組織の変化などが挙げられます。仕事のプレッシャーの増加に関する急性片頭痛治療では、特に過酷な職場環境において、ストレスによって誘発または悪化する可能性のある片頭痛症状の管理に焦点を当てています。例えば、2022年10月、米国の心理学者団体である米国心理学会は、職場でのストレスが依然として重要な問題であり、従業員の77％が過去1ヵ月間に仕事関連のストレスを経験していると報告しました。さらに、57％の従業員が、感情的疲労（31％）などの悪影響に悩まされていると述べており、多くの場合、職場での燃え尽き症候群と関連しています。したがって、仕事のプレッシャーの増大が急性片頭痛治療市場の成長に拍車をかけています。

急性片頭痛治療市場の主要企業は、片頭痛緩和の効果と利便性を向上させるため、点鼻薬などの革新的ソリューションの開発に注力しています。片頭痛の点鼻薬は鼻腔から薬剤を投与するため、経口薬に比べて吸収が早く、短時間で緩和されるという利点があります。例えば、2023年3月、米国のバイオテクノロジー企業であるPfizer Inc.は、FDAによって承認されたZAVZPRET（zavegepant）片頭痛点鼻スプレーを発表しました。この点鼻スプレーは、CGRP受容体拮抗薬であるzavegepantを使用し、カルシトニン遺伝子関連ペプチド（CGRP）経路を遮断することで、片頭痛を迅速かつ的を絞って緩和します。ZAVZPRETの速効性の製剤は15分以内に緩和をもたらし、重度の片頭痛症状からの迅速な緩和を求める人々にとって便利な選択肢となります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界急性片頭痛治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の急性片頭痛治療市場：成長率分析
• 世界の急性片頭痛治療市場の実績：規模と成長, 2019-2024
• 世界の急性片頭痛治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界急性片頭痛治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の急性片頭痛治療市場薬剤の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• トリプタン
• カルシトニン遺伝子関連ペプチド拮抗薬
• 非ステロイド性抗炎症薬
• ベータアドレナリン
• 麦角アルカロイド
• その他の薬物の種類
• 世界の急性片頭痛治療市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射
• その他の投与経路
• 世界の急性片頭痛治療市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• ドラッグストア
• eコマース
• 世界の急性片頭痛治療市場トリプタンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• スマトリプタン
• リザトリプタン
• ゾルミトリプタン
• エレトリプタン
• 世界の急性片頭痛治療市場カルシトニン遺伝子関連ペプチド（CGRP）拮抗薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• エレヌマブ
• フレマネズマブ
• ガルカネズマブ
• 世界の急性片頭痛治療市場非ステロイド性抗炎症薬（NSAIDs）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• イブプロフェン
• ナプロキセン
• ジクロフェナク
• 世界の急性片頭痛治療市場、ベータアドレナリンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• プロプラノロール
• メトプロロール
• アテノロール
• 世界の急性片頭痛治療市場麦角アルカロイドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• エルゴタミン
• ジヒドロエルゴタミン
• 世界の急性片頭痛治療市場、その他の薬剤タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 制吐薬
• 抗うつ薬
• コルチコステロイド

第7章 地域別・国別分析

• 世界の急性片頭痛治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の急性片頭痛治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 急性片頭痛治療市場：競合情勢
• 急性片頭痛治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson And Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AstraZeneca PLC
• Novartis AG
• GlaxoSmithKline plc
• Eli Lilly and Company
• Amgen Inc.
• Viatris Inc.
• Allergan plc
• Teva Pharmaceutical Industries Ltd.
• Bausch Health Companies Inc.
• Endo International plc
• Supernus Pharmaceuticals Inc.
• Collegium Pharmaceutical Inc.
• Upsher-Smith Laboratories LLC
• BioDelivery Sciences International Inc.
• Axsome Therapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 急性片頭痛治療市場2029：新たな機会を提供する国
• 急性片頭痛治療市場2029：新たな機会を提供するセグメント
• 急性片頭痛治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Acute migraine treatments involve therapies aimed at providing immediate relief from migraine attacks by addressing symptoms such as intense headaches, nausea, and heightened sensitivity to light and sound. These treatments are designed to reduce the severity and duration of migraines, improving patient comfort and functionality during episodes.

The primary types of drugs used for acute migraine treatment include triptans, calcitonin gene-related peptide (CGRP) antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), beta-adrenergic blockers, ergot alkaloids, and others. Triptans are medications that specifically target serotonin 1B and 1D receptors, leading to vasoconstriction and reducing the release of inflammatory substances. They are considered specific treatments for migraines and are commonly used for acute relief. These medications can be administered orally, through injection, or by other methods and are available through various distribution channels, including hospital pharmacies, retail pharmacies, drug stores, and online platforms.

The acute migraine treatments market research report is one of a series of new reports from The Business Research Company that provides acute migraine treatments market statistics, including acute migraine treatments industry global market size, regional shares, competitors with an acute migraine treatments market share, detailed acute migraine treatments market segments, market trends, and opportunities, and any further data you may need to thrive in the acute migraine treatments industry. This acute migraine treatments research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The acute migraine treatment market size has grown rapidly in recent years. It will grow from $2.6 billion in 2024 to $2.91 billion in 2025 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to the increasing prevalence of migraine, growth of specialty clinics, increasing funding for migraine research, growth in clinical trials, and increasing use of preventive medications.

The acute migraine treatment market size is expected to see rapid growth in the next few years. It will grow to $4.44 billion in 2029 at a compound annual growth rate (CAGR) of 11.2%. The growth in the forecast period can be attributed to the increasing prevalence of migraine, growing investment in migraine research, rising demand for non-invasive treatment options, rising demand for quick-acting relief options, and growing emphasis on patient-centric drug development. Major trends in the forecast period include technological advancements, the adoption of neuromodulation devices, personalized medicine, telemedicine, and diagnostic tools.

The growing work pressure is anticipated to drive the growth of the acute migraine treatment market moving forward. Work pressure refers to the mental, emotional, and physical strain that employees experience due to the demands and challenges of their job roles. Contributing factors to the increase in work pressure include tight deadlines, insufficient resources and support, poor work-life balance, unclear job roles, interpersonal conflicts, and organizational changes. Acute migraine treatment for heightened work pressure focuses on managing migraine symptoms that may be triggered or worsened by stress, particularly in demanding work environments. For example, in October 2022, the American Psychological Association, a US-based association of psychologists, reported that workplace stress remains a significant issue, with 77% of employees experiencing work-related stress in the past month. Furthermore, 57% of employees mentioned suffering negative effects, such as emotional exhaustion (31%), often associated with workplace burnout. Hence, the increasing work pressure is fueling the growth of the acute migraine treatment market.

Leading companies in the acute migraine treatment market are focused on developing innovative solutions, such as nasal sprays, to improve the effectiveness and convenience of migraine relief. Migraine nasal sprays administer medication through the nasal passages, offering the benefit of rapid absorption and quicker relief compared to oral medications. For example, in March 2023, Pfizer Inc., a US-based biotechnology company, introduced ZAVZPRET (zavegepant) Migraine Nasal Spray, approved by the FDA. This nasal spray uses zavegepant, a CGRP receptor antagonist, to block the calcitonin gene-related peptide (CGRP) pathway, providing swift and targeted relief from migraines. ZAVZPRET's fast-acting formulation offers relief within 15 minutes, making it a convenient choice for those seeking quick relief from severe migraine symptoms.

In October 2022, Pfizer Inc. acquired Biohaven Pharmaceutical Holding Company Ltd. for $11.6 billion. This acquisition aims to enhance Pfizer's position in the neurology and pain management sectors by integrating Biohaven's innovative migraine treatments and other neurological therapies. Biohaven Pharmaceutical Holding Company Ltd. specializes in treatments for acute migraines.

Major companies operating in the acute migraine treatment market are Pfizer Inc., Johnson And Johnson, Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Viatris Inc., Allergan plc, Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Endo International plc, Supernus Pharmaceuticals Inc., Collegium Pharmaceutical Inc., Upsher-Smith Laboratories LLC, BioDelivery Sciences International Inc., Axsome Therapeutics Inc., Impel NeuroPharma Inc., Currax Pharmaceuticals LLC, Satsuma Pharmaceuticals Inc.

North America was the largest region in the acute migraine treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute migraine treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the acute migraine treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The acute migraine treatment market consists of revenues earned by entities by providing emergency room (ER) services, headache centers, primary care physicians, and pain management. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute migraine treatment market also includes sales of acetaminophen, anti-nausea medications, CGRP antagonists, and transcranial magnetic stimulation (TMS) devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Acute Migraine Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on acute migraine treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for acute migraine treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The acute migraine treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Triptans; Calcitonin Gene-Related Peptide Antagonist; Nonsteroidal Anti-Inflammatory Drugs; Beta-Adrenergic; Ergot Alkaloids; Other Drug Types
• 2) By Route Of Administration: Oral; Injection; Other Routes Of Administration
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Drug Stores; E-Commerce
• Subsegments:
• 1) By Triptans: Sumatriptan; Rizatriptan; Zolmitriptan; Eletriptan
• 2) By Calcitonin Gene-Related Peptide (CGRP) Antagonists: Erenumab; Fremanezumab; Galcanezumab
• 3) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen; Naproxen; Diclofenac
• 4) By Beta-Adrenergic: Propranolol; Metoprolol; Atenolol
• 5) By Ergot Alkaloids: Ergotamine; Dihydroergotamine
• 6) By Other Drug Types: Antiemetic Drugs; Antidepressants; Corticosteroids
• Companies Mentioned: Pfizer Inc.; Johnson And Johnson; Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Acute Migraine Treatment Market Characteristics

3. Acute Migraine Treatment Market Trends And Strategies

4. Acute Migraine Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Acute Migraine Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Acute Migraine Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Acute Migraine Treatment Market Growth Rate Analysis
• 5.4. Global Acute Migraine Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Acute Migraine Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Acute Migraine Treatment Total Addressable Market (TAM)

6. Acute Migraine Treatment Market Segmentation

• 6.1. Global Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Triptans
• Calcitonin Gene-Related Peptide Antagonist
• Nonsteroidal Anti-Inflammatory Drugs
• Beta-Adrenergic
• Ergot Alkaloids
• Other Drug Types
• 6.2. Global Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injection
• Other Routes Of Administration
• 6.3. Global Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• E-Commerce
• 6.4. Global Acute Migraine Treatment Market, Sub-Segmentation Of Triptans, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sumatriptan
• Rizatriptan
• Zolmitriptan
• Eletriptan
• 6.5. Global Acute Migraine Treatment Market, Sub-Segmentation Of Calcitonin Gene-Related Peptide (CGRP) Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Erenumab
• Fremanezumab
• Galcanezumab
• 6.6. Global Acute Migraine Treatment Market, Sub-Segmentation Of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ibuprofen
• Naproxen
• Diclofenac
• 6.7. Global Acute Migraine Treatment Market, Sub-Segmentation Of Beta-Adrenergic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Propranolol
• Metoprolol
• Atenolol
• 6.8. Global Acute Migraine Treatment Market, Sub-Segmentation Of Ergot Alkaloids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ergotamine
• Dihydroergotamine
• 6.9. Global Acute Migraine Treatment Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antiemetic Drugs
• Antidepressants
• Corticosteroids

7. Acute Migraine Treatment Market Regional And Country Analysis

• 7.1. Global Acute Migraine Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Acute Migraine Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Acute Migraine Treatment Market

• 8.1. Asia-Pacific Acute Migraine Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Acute Migraine Treatment Market

• 9.1. China Acute Migraine Treatment Market Overview
• 9.2. China Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Acute Migraine Treatment Market

• 10.1. India Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Acute Migraine Treatment Market

• 11.1. Japan Acute Migraine Treatment Market Overview
• 11.2. Japan Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Acute Migraine Treatment Market

• 12.1. Australia Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Acute Migraine Treatment Market

• 13.1. Indonesia Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Acute Migraine Treatment Market

• 14.1. South Korea Acute Migraine Treatment Market Overview
• 14.2. South Korea Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Acute Migraine Treatment Market

• 15.1. Western Europe Acute Migraine Treatment Market Overview
• 15.2. Western Europe Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Acute Migraine Treatment Market

• 16.1. UK Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Acute Migraine Treatment Market

• 17.1. Germany Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Acute Migraine Treatment Market

• 18.1. France Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Acute Migraine Treatment Market

• 19.1. Italy Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Acute Migraine Treatment Market

• 20.1. Spain Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Acute Migraine Treatment Market

• 21.1. Eastern Europe Acute Migraine Treatment Market Overview
• 21.2. Eastern Europe Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Acute Migraine Treatment Market

• 22.1. Russia Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Acute Migraine Treatment Market

• 23.1. North America Acute Migraine Treatment Market Overview
• 23.2. North America Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Acute Migraine Treatment Market

• 24.1. USA Acute Migraine Treatment Market Overview
• 24.2. USA Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Acute Migraine Treatment Market

• 25.1. Canada Acute Migraine Treatment Market Overview
• 25.2. Canada Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Acute Migraine Treatment Market

• 26.1. South America Acute Migraine Treatment Market Overview
• 26.2. South America Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Acute Migraine Treatment Market

• 27.1. Brazil Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Acute Migraine Treatment Market

• 28.1. Middle East Acute Migraine Treatment Market Overview
• 28.2. Middle East Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Acute Migraine Treatment Market

• 29.1. Africa Acute Migraine Treatment Market Overview
• 29.2. Africa Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Acute Migraine Treatment Market Competitive Landscape And Company Profiles

• 30.1. Acute Migraine Treatment Market Competitive Landscape
• 30.2. Acute Migraine Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson And Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Acute Migraine Treatment Market Other Major And Innovative Companies

• 31.1. AstraZeneca PLC
• 31.2. Novartis AG
• 31.3. GlaxoSmithKline plc
• 31.4. Eli Lilly and Company
• 31.5. Amgen Inc.
• 31.6. Viatris Inc.
• 31.7. Allergan plc
• 31.8. Teva Pharmaceutical Industries Ltd.
• 31.9. Bausch Health Companies Inc.
• 31.10. Endo International plc
• 31.11. Supernus Pharmaceuticals Inc.
• 31.12. Collegium Pharmaceutical Inc.
• 31.13. Upsher-Smith Laboratories LLC
• 31.14. BioDelivery Sciences International Inc.
• 31.15. Axsome Therapeutics Inc.

32. Global Acute Migraine Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Acute Migraine Treatment Market

34. Recent Developments In The Acute Migraine Treatment Market

35. Acute Migraine Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Acute Migraine Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Acute Migraine Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Acute Migraine Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer